Identification of P-cadherin in primary melanoma using a tissue microarrayer: Prognostic implications in a patient cohort with long-term follow up

Annals of Plastic Surgery

Volumn 55, Issue 3, 2005, Pages 316-320

  Pacifico, Marc D ^a   Grover, Rajiv ^a   Richman, Paul I ^a   Buffa, Francesca ^a   Daley, Fances M ^a   Wilson, George D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Melanoma; P cadherin; Prognosis; Tissue microarray

Indexed keywords

CADHERIN; P CADHERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE; TECHNOLOGY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 24044523201     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000171429.19320.ce     Document Type: Article

References (23)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127: 392-399.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19: 3622-3634.
3. Thomas JM, Clark MA. Are there guidance issues relating to sentinel node biopsy for melanoma in the UK? Br J Plast Surg. 2004;57:689-690.
4. Statius Muller MG, van Leeuwen PAM, van Diest PJ, et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg. 2002;26:1405-1411.
5. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62-70.
6. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage 1 melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
7. Fearfield LA, Rowe A, Francis N, et al. Clinico-pathological features of relapsing very thin melanoma. Clin Exp Dermatol. 2001;26:686-695.
8. Salti GI, Kansagra A, Warso MA, et al. Clinical node-negative thick melanoma. Arch Surg. 2002;137:291-295.
9. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 1999;18:345-357.
10. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000; 156:1515-1525.
11. Hsu MY, Wheelock MJ, Johnson KR, et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc. 1996;1:188-194.
12. Sakaki T, Tamura I, Kadota H, et al. Changing expression of E- and P-cadherin during rat tongue carcinogenesis induced by 4-nitroquinolone 1-oxide. J Oral Pathol Med. 2003 32:530-537.
13. Paredes J, Milanezi F, Reis-Filho JS, et al. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract. 2002;198:795-801.
14. Sanders DS, Blessing K, Hassan GA, et al. Alterations in cadherin and catenin expression during the biological progression of melanoeytic tumors. Mol Pathol. 1999;52:151-157.
15. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
16. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-3648.
17. Pacifico MD, Grover R, Richman P, et al. Validation of tissue microarray for immunohistochemical profiling of melanoma. Mel Res. 2004;14: 39-42.
18. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966-1975.
19. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose Interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
20. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol. 2001;19: 568-576.
21. Hieken TJ, Farolan M, Ronan SG, et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res. 1996;63:169-173.
22. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536.
23. Seline PC, Norris DA, Horikawa T, et al. Expression of E and P-cadherin by melanoma cells decreases in progressive melanomas and following ultraviolet radiation. J Invest Dermatol. 1996;106: 1320-1324.